|
GARS expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
6.94389999944534E-07 |
| Normal-vs-Stage3 |
1.33226762955019E-15 |
| Normal-vs-Stage4 |
2.6842000000471E-06 |
| Stage1-vs-Stage2 |
3.971600E-01 |
| Stage1-vs-Stage3 |
1.715200E-01 |
| Stage1-vs-Stage4 |
4.282000E-01 |
| Stage2-vs-Stage3 |
1.529040E-01 |
| Stage2-vs-Stage4 |
9.381600E-01 |
| Stage3-vs-Stage4 |
1.590400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62436730732907E-12 |
| Normal-vs-AfricanAmerican |
2.03600000003856E-06 |
| Normal-vs-Asian |
6.81230000187938E-08 |
| Caucasian-vs-AfricanAmerican |
8.359600E-01 |
| Caucasian-vs-Asian |
4.899400E-01 |
| AfricanAmerican-vs-Asian |
7.323600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.13242748511766E-14 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
9.582100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
1.45750000957179E-09 |
| Normal-vs-Age(81-100Yrs) |
1.1575000002928E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.262000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.805400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.527900E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.492600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.178400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.737810E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.853800E-01 |
| Classical-VS-Follicular |
9.317100E-03 |
| Classical-VS-Other |
9.808400E-04 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
7.102500E-02 |
| Tall-VS-Other |
1.344710E-03 |
| Tall-VS-Normal |
1.74580000011915E-07 |
| Follicular-VS-Other |
4.810400E-02 |
| Follicular-VS-Normal |
3.94510000001347E-06 |
| Other-VS-Normal |
2.433000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
1.42520000023794E-07 |
| N0-vs-N1 |
6.980600E-01 |
|
|
